Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Why Viking Therapeutics Stock Could Take Off Later This Year
03:00pm, Monday, 23'rd Mar 2026
Viking's GLP-1 drug, VK2735, is currently in the midst of multiple clinical trials. The company is evaluating whether it can be taken monthly for maintenance dosing.
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
08:30pm, Tuesday, 17'th Mar 2026
Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share. Viking aims to enter this market -- and so far, its clinical trial results have been strong.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
06:45pm, Monday, 16'th Mar 2026
Viking Therapeutics, Inc. (VKTX) reached $36.01 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
04:00pm, Monday, 16'th Mar 2026
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
3 Companies at the Forefront of the GLP-1 Pill Wars
07:44am, Monday, 16'th Mar 2026
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss dru
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report?
12:36pm, Friday, 13'th Mar 2026
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026
05:45am, Wednesday, 11'th Mar 2026
A maintenance study could shed light on the tolerability of VK2735's oral formulation in 2026, ahead of the Phase 3 trial's conclusion. Viking Therapeutics has two Phase 3 trials in process for the su
Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
01:10pm, Tuesday, 10'th Mar 2026
Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street
10:00am, Monday, 09'th Mar 2026
Viking Therapeutics' leading candidate should complete some ongoing phase 3 studies next year. The stock might soar, depending on how strong the data is.
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
06:45pm, Thursday, 05'th Mar 2026
Viking Therapeutics, Inc. (VKTX) closed at $31.51 in the latest trading session, marking a -1.96% move from the prior day.
Viking Therapeutics to Participate at Upcoming Investor Conferences
04:03pm, Thursday, 05'th Mar 2026
SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
06:45pm, Friday, 27'th Feb 2026
Viking Therapeutics, Inc. (VKTX) reached $33.84 at the closing of the latest trading day, reflecting a +2.64% change compared to its last close.
Viking Therapeutics: The High-Stakes Weight Loss Contender
02:37pm, Thursday, 26'th Feb 2026
The pharmaceutical industry is currently witnessing a historic gold rush surrounding obesity treatments. While industry titans like Novo Nordisk NYSE: NVO and Eli Lilly NYSE: LLY dominate the headline
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.
08:30pm, Monday, 23'rd Feb 2026
Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and regula
Viking Therapeutics Stock Gains Amid Obesity Drug Buzz
02:29pm, Monday, 23'rd Feb 2026
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro bra
